These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 26870974)
1. [FREQUENCY OF POLYMORPHISM OF VKORC1 AND CYP2C9 GENES IN TWO REGIONS OF GEORGIA]. Jokhadze T; Kakauridze N; Buadze T; Gaiozishvili M; Lezhava T Georgian Med News; 2016 Jan; (250):46-51. PubMed ID: 26870974 [TBL] [Abstract][Full Text] [Related]
2. FREQUENCY OF VKORC1 AND CYP2C9 GENES POLYMORPHISM IN ABKHAZIAN POPULATION. Lezhava T; Kakauridze N; Jokhadze T; Buadze T; Gaiozishvili M; Gargulia K; Sigua T Georgian Med News; 2023 May; (338):96-101. PubMed ID: 37419479 [TBL] [Abstract][Full Text] [Related]
3. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance. Azzam H; Elwakeel H; Awad I; El-Farahaty R; El-Gilany AH; El-Sharawy S Blood Coagul Fibrinolysis; 2016 Mar; 27(2):121-6. PubMed ID: 24978953 [TBL] [Abstract][Full Text] [Related]
4. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage]. Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578 [TBL] [Abstract][Full Text] [Related]
5. Genotyping of CYP2C9 and VKORC1 polymorphisms predicts south Indian patients with deep vein thrombosis as fast metabolizers of warfarin/acenocoumarin. Arunkumar G; Vishnuprabu D; Nupur B; Vidyasagaran T; Murugan AK; Munirajan AK Drug Discov Ther; 2017; 11(4):198-205. PubMed ID: 28867752 [TBL] [Abstract][Full Text] [Related]
6. [Impact of CYP2C9 and VKORC1 polymorphism on warfarin response during initiation of therapy]. Liu Y; Zhong SL; Tan HH; Yang M; Fei HW; Yu XY; Lin SG Zhonghua Xin Xue Guan Bing Za Zhi; 2011 Oct; 39(10):929-35. PubMed ID: 22321278 [TBL] [Abstract][Full Text] [Related]
7. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome. Ghozlan MF; Foad DA; Darwish YW; Saad AA Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611 [TBL] [Abstract][Full Text] [Related]
8. Frequency of polymorphisms in the CYP2C9, VKORC1, and CYP4F2 genes related to the metabolism of Warfarin in healthy donors from Cali, Colombia. Giraldo-Ocampo S; Diaz-Ordoñez L; Silva-Cuero YK; Gutierrez-Medina JD; Candelo E; Diaz JA; Pachajoa H Medicine (Baltimore); 2023 Jul; 102(30):e34204. PubMed ID: 37505171 [TBL] [Abstract][Full Text] [Related]
9. The frequency of CYP2C9, VKORC1, and CYP4F2 polymorphisms in Russian patients with high thrombotic risk. Ivashchenko D; Rusin I; Sychev D; Grachev A Medicina (Kaunas); 2013; 49(12):517-21. PubMed ID: 24858991 [TBL] [Abstract][Full Text] [Related]
10. The effect of CYP2C9 and VKORC1 genetic polymorphisms on warfarin dose requirements in a pediatric population. Dilge Taşkın B; Kula S; Ergün MA; Altun D; Olguntürk R; Tunaoğlu FS; Oğuz AD; Gürsel T Anatol J Cardiol; 2016 Oct; 16(10):791-796. PubMed ID: 27182616 [TBL] [Abstract][Full Text] [Related]
11. Effect of VKORC1 and CYP2C9 polymorphisms on warfarin dose requirement in Bangladeshi population. Chowdhury ZS; Shahjin F; Akter F; Ahmed M; Islam MS; Bin Sayeed MS; Islam R; Hasnat A Pak J Pharm Sci; 2017 Mar; 30(2):341-346. PubMed ID: 28649054 [TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study. de Oliveira Almeida VC; Ribeiro DD; Gomes KB; Godard AL Mol Diagn Ther; 2014 Dec; 18(6):675-83. PubMed ID: 25312789 [TBL] [Abstract][Full Text] [Related]
13. VKORC1 and CYP2C9 genotype distribution in Asian countries. Gaikwad T; Ghosh K; Shetty S Thromb Res; 2014 Sep; 134(3):537-44. PubMed ID: 24908449 [TBL] [Abstract][Full Text] [Related]
14. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement. Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036 [TBL] [Abstract][Full Text] [Related]
15. Effect of gene polymorphims on the warfarin treatment at initial stage. Liu J; Jiang HH; Wu DK; Zhou YX; Ye HM; Li X; Luo ZY; Guo Z; Zhang YL; Wang YC; Zhang W; Zhou HH; Wang LS Pharmacogenomics J; 2017 Jan; 17(1):47-52. PubMed ID: 26644206 [TBL] [Abstract][Full Text] [Related]
16. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. An SH; Chang BC; Lee KE; Gwak HS Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945 [TBL] [Abstract][Full Text] [Related]
17. Association between the CYP2C9 polymorphism and the drug metabolism phenotype. Topić E; Stefanović M; Samardzija M Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1 - implications for warfarin management and outcome in Croatian patients with acute stroke. Supe S; Božina N; Matijević V; Bazina A; Mišmaš A; Ljevak J; Alvir D; Habek M; Poljaković Z J Neurol Sci; 2014 Aug; 343(1-2):30-5. PubMed ID: 24974237 [TBL] [Abstract][Full Text] [Related]
19. Improvements in CYP2C9 Genotyping Accuracy Are Needed: A Report of the First Proficiency Testing for Warfarin-related CYP2C9 and VKORC1 Genotyping in China. Lin G; Yi L; Zhang K; Sun Y; Wang L; Zhang R; Xie J; Li J J Cardiovasc Pharmacol; 2015 Aug; 66(2):129-34. PubMed ID: 25815675 [TBL] [Abstract][Full Text] [Related]
20. Association of Genetic Polymorphisms in the VKORC1 and CYP2C9 Genes with Warfarin Dosage in a Group of Kuwaiti Individuals. Alrashid MH; Al-Serri A; Alshemmari SH; Koshi P; Al-Bustan SA Mol Diagn Ther; 2016 Apr; 20(2):183-90. PubMed ID: 26940072 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]